Kamari was established at the end of 2018 by the Israeli based biotechnology funds Pontifax and Arkin Bioholdings. Up to the current investment, $16 million were invested in Kamari. The company develops topical and oral drugs based on proprietary small molecules that inhibit an ion channel designated TRPV3. These drugs are intended for the treatment of various dermatological diseases, such as keratoderma, Lichen Simplex Chronicus and other severe genetic skin disorders.